Lupin rises after US FDA gives pharma firm EIR for its Aurangabad facility
Lupin said on Tuesday that it had received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Lupin Share Price: Lupin rose on BSE on Wednesday (April 24, 2024) after receiving EIR from US FDA for its Aurangabad manufacturing facility.
The stock that began its journey on Wednesday at Rs 1,595.00 jumped to the day's high of Rs 1,602.50, a 1.39 per cent rise from its close of Rs 1580.55 a day ago.
Lupin shares were trading up by 0.75 per cent, or Rs 11.85, at Rs 1592.40 each at 9:55 am on Wednesday.
US FDA's clean chit
Lupin said on Tuesday that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Aurangabad manufacturing facility.
The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
“We are pleased to receive the EIR with VAI status from the U.S. FDA as an outcome of the recent inspection of our Aurangabad facility. It is a testament to our commitment to consistently upholding the highest standards of compliance and providing high-quality healthcare solutions to patients worldwide,” said Nilesh Gupta, Managing Director, Lupin.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.